Biomarkers in Nonmetastatic Castrate-Resistant Prostate Cancer: A Step in the Right Direction

Affiliations

¹ Harvard Radiation Oncology Program, Boston, Massachusetts.
² Department of Radiation Oncology, University of Miami, Miami, Florida.
³ Department of Radiation Oncology, Memorial Sloan Kettering Cancer, New York, New York.

Comment

David D Yang et al. JAMA Oncol. 2021.

. 2021 Jul 1;7(7):1014-1015.

doi: 10.1001/jamaoncol.2021.1358.

¹ Harvard Radiation Oncology Program, Boston, Massachusetts.
² Department of Radiation Oncology, University of Miami, Miami, Florida.
³ Department of Radiation Oncology, Memorial Sloan Kettering Cancer, New York, New York.

No abstract available

Comment on

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, Small EJ. Feng FY, et al. JAMA Oncol. 2021 Jul 1;7(7):1005-1014. doi: 10.1001/jamaoncol.2021.1463. JAMA Oncol. 2021. PMID: 34081076 Free PMC article. Clinical Trial.